Adipocytokines Obesity and Insulin Resistance During Combined Androgen Blockade for Prostate Cancer: Evidence for a Distinct Hypogonadal Metabolic Syndrome?

摘要

ObjectivesGonadotropin-releasing hormone agonists increase fat mass, decrease insulin sensitivity, and increase serum triglycerides–changes suggestive of the classic metabolic syndrome. These analyses were designed to assess the effects of gonadotropin-releasing hormone agonist treatment on other markers of the metabolic syndrome including adiponectin, resistin, and plasminogen activator inhibitor type 1 (PAI-1) levels and to evaluate relationships between changes in adipocytokines, body composition, and insulin sensitivity.